POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

Potassium chloride replaces potassium ions, essential for maintaining intracellular fluid balance, nerve impulse transmission, and muscle contraction. Dextrose provides a source of calories and may help prevent ketosis. Sodium chloride replaces sodium and chloride ions, maintaining osmotic pressure and acid-base balance.

What the body does with it

Metabolism	Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to carbon dioxide and water, providing energy; sodium and chloride are excreted primarily by the kidneys and are not significantly metabolized.
Excretion	Potassium is primarily excreted by the kidneys (90%), with small amounts lost in feces (10%). Minor losses occur through sweat. Renal excretion involves glomerular filtration and tubular secretion, with aldosterone-regulated reabsorption. Biliary excretion is negligible.
Half-life	Potassium has a biological half-life of approximately 8 hours in healthy adults, but this is highly variable based on renal function and total body stores. The terminal elimination half-life is not classically defined as it follows multicompartment kinetics; the redistribution half-life is about 1 hour. Clinical context: half-life is prolonged in renal impairment and with high potassium intake.
Protein binding	Potassium is not significantly bound to plasma proteins; protein binding is less than 10% and not clinically relevant. It exists primarily as free ions in plasma.
Volume of Distribution	The apparent volume of distribution for potassium is 0.06-0.1 L/kg (total body water distribution). Potassium is predominantly intracellular, so the Vd reflects the extracellular compartment. Clinical meaning: a small Vd indicates that the drug remains largely in plasma and interstitial fluid; changes in Vd can occur in acid-base disorders or with shifts between intra- and extracellular spaces.
Bioavailability	Oral potassium chloride: bioavailability is 90-100% as it is efficiently absorbed in the gastrointestinal tract. Intravenous: 100% bioavailable. Rectal: variable and not clinically used for systemic effect.
Onset of Action	Intravenous infusion: onset within seconds to minutes, as plasma potassium levels rise immediately. Oral administration: onset of gastrointestinal absorption occurs within 1-2 hours, with peak serum levels at 2-4 hours post-dose.
Duration of Action	Intravenous: effect persists for about 8-12 hours after infusion, depending on distribution and elimination. Oral: duration of action is approximately 6-8 hours for serum potassium elevation, but sustained-release formulations can extend up to 12 hours. Clinical note: Duration is highly dependent on renal function and concurrent medications (e.g., diuretics, ACE inhibitors).

Classification & Brands

Dosing & administration

Intravenous infusion; rate not to exceed 0.5-1 mEq/kg/hour (maximum 10-20 mEq/hour) with continuous ECG monitoring; typical adult dose: 20-40 mEq potassium chloride in 1 L of the specified solution infused over 4-6 hours.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min) with oliguria or anuria; use with caution in mild-moderate impairment (GFR 30-59 mL/min) with reduced infusion rates and frequent monitoring of serum potassium and renal function.
Liver impairment	No specific dose adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh class C) due to increased risk of fluid overload and electrolyte disturbances; consider reduced infusion rates and monitoring.
Pediatric use	Intravenous infusion; usual dose: 0.5-1 mEq/kg per day, adjusted based on serum potassium; maximum infusion rate: 0.5 mEq/kg/hour (not to exceed 10 mEq per dose). Requires continuous ECG monitoring and use of infusion pump.
Geriatric use	Use lower initial doses and slower infusion rates (maximum 10 mEq/hour) due to decreased renal function and higher risk of hyperkalemia; monitor serum potassium and renal function frequently; adjust for comorbidities and concurrent medications.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium chloride, dextrose, and sodium chloride are normal constituents of breast milk; M/P ratio not established. Administration at recommended doses is considered compatible with breastfeeding. Avoid excessive doses that could alter milk composition or maternal electrolyte balance.
Teratogenic Risk	Pregnancy category C. Potassium chloride: no known teratogenic effects at therapeutic doses; maternal hyperkalemia can cause fetal bradycardia or arrhythmia. Dextrose: hyperglycemia may be associated with fetal macrosomia, neonatal hypoglycemia, or congenital anomalies if uncontrolled. Sodium chloride: excessive intake may lead to maternal edema or hypertension, potentially affecting placental perfusion. No specific first-trimester risks reported, but use only if clearly needed. Second/third trimester: monitor for electrolyte imbalances and glucose control.

Warnings & precautions

■ FDA Black Box Warning

Potassium chloride injection concentrate must be diluted before use. Direct injection of undiluted potassium chloride can cause fatal cardiac arrhythmias.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment with oliguria or anuria","Untreated Addison's disease","Adynamic ileus","Acute dehydration","Heat cramps","Concurrent use with potassium-sparing diuretics"]

Clinical Precautions

Precautions

["Monitor serum potassium levels to avoid hyperkalemia or hypokalemia","Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Risk of fluid overload in patients with heart failure or renal impairment","Risk of phlebitis and extravasation","Dextrose-containing solutions may cause hyperglycemia"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

What the body does with it

Metabolism	Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized to carbon dioxide and water, providing energy; sodium and chloride are excreted primarily by the kidneys and are not significantly metabolized.
Excretion	Potassium is primarily excreted by the kidneys (90%), with small amounts lost in feces (10%). Minor losses occur through sweat. Renal excretion involves glomerular filtration and tubular secretion, with aldosterone-regulated reabsorption. Biliary excretion is negligible.
Half-life	Potassium has a biological half-life of approximately 8 hours in healthy adults, but this is highly variable based on renal function and total body stores. The terminal elimination half-life is not classically defined as it follows multicompartment kinetics; the redistribution half-life is about 1 hour. Clinical context: half-life is prolonged in renal impairment and with high potassium intake.
Protein binding	Potassium is not significantly bound to plasma proteins; protein binding is less than 10% and not clinically relevant. It exists primarily as free ions in plasma.
Volume of Distribution	The apparent volume of distribution for potassium is 0.06-0.1 L/kg (total body water distribution). Potassium is predominantly intracellular, so the Vd reflects the extracellular compartment. Clinical meaning: a small Vd indicates that the drug remains largely in plasma and interstitial fluid; changes in Vd can occur in acid-base disorders or with shifts between intra- and extracellular spaces.
Bioavailability	Oral potassium chloride: bioavailability is 90-100% as it is efficiently absorbed in the gastrointestinal tract. Intravenous: 100% bioavailable. Rectal: variable and not clinically used for systemic effect.
Onset of Action	Intravenous infusion: onset within seconds to minutes, as plasma potassium levels rise immediately. Oral administration: onset of gastrointestinal absorption occurs within 1-2 hours, with peak serum levels at 2-4 hours post-dose.
Duration of Action	Intravenous: effect persists for about 8-12 hours after infusion, depending on distribution and elimination. Oral: duration of action is approximately 6-8 hours for serum potassium elevation, but sustained-release formulations can extend up to 12 hours. Clinical note: Duration is highly dependent on renal function and concurrent medications (e.g., diuretics, ACE inhibitors).

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min) with oliguria or anuria; use with caution in mild-moderate impairment (GFR 30-59 mL/min) with reduced infusion rates and frequent monitoring of serum potassium and renal function.
Liver impairment	No specific dose adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh class C) due to increased risk of fluid overload and electrolyte disturbances; consider reduced infusion rates and monitoring.
Pediatric use	Intravenous infusion; usual dose: 0.5-1 mEq/kg per day, adjusted based on serum potassium; maximum infusion rate: 0.5 mEq/kg/hour (not to exceed 10 mEq per dose). Requires continuous ECG monitoring and use of infusion pump.
Geriatric use	Use lower initial doses and slower infusion rates (maximum 10 mEq/hour) due to decreased renal function and higher risk of hyperkalemia; monitor serum potassium and renal function frequently; adjust for comorbidities and concurrent medications.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium chloride, dextrose, and sodium chloride are normal constituents of breast milk; M/P ratio not established. Administration at recommended doses is considered compatible with breastfeeding. Avoid excessive doses that could alter milk composition or maternal electrolyte balance.
Teratogenic Risk	Pregnancy category C. Potassium chloride: no known teratogenic effects at therapeutic doses; maternal hyperkalemia can cause fetal bradycardia or arrhythmia. Dextrose: hyperglycemia may be associated with fetal macrosomia, neonatal hypoglycemia, or congenital anomalies if uncontrolled. Sodium chloride: excessive intake may lead to maternal edema or hypertension, potentially affecting placental perfusion. No specific first-trimester risks reported, but use only if clearly needed. Second/third trimester: monitor for electrolyte imbalances and glucose control.

Warnings & precautions

■ FDA Black Box Warning

Potassium chloride injection concentrate must be diluted before use. Direct injection of undiluted potassium chloride can cause fatal cardiac arrhythmias.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment with oliguria or anuria","Untreated Addison's disease","Adynamic ileus","Acute dehydration","Heat cramps","Concurrent use with potassium-sparing diuretics"]